Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Mathew Blackman upgraded Tandem Diabetes Care (TNDM) from Hold to Buy and increased the price target from $24 to $37.

March 26, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel upgraded Tandem Diabetes Care to Buy from Hold and raised the price target to $37 from $24.
Upgrades by analysts, especially from Hold to Buy, typically signal a positive outlook on the stock, suggesting potential upside. The significant increase in the price target further underscores the analyst's confidence in the company's future performance, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100